ReviewMini reviews in medicinal chemistry2026
Critical Relationship Between Iron Deficiency Anaemia (IDA) and Glycated Haemoglobin (HbA1c): An Updated Review.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThis review explores the complex relationship between Iron Deficiency Anaemia (IDA) and glycated haemoglobin (HbA1c) levels, a critical marker for diabetes mellitus. The objective is to evaluate how IDA influences HbA1c measurements and its implications for diabetes diagnosis and management, particularly in populations with high IDA prevalence.
methodsA narrative mini-review was conducted, synthesizing evidence from studies identified through PubMed, MEDLINE, and Google Scholar. The search focused on English-language articles published between 1982 and 2024, adhering to PRISMA guidelines. Studies were selected based on their relevance to IDA and HbA1c, with 57 articles meeting the inclusion criteria after rigorous screening.
resultsThe review revealed conflicting findings: some studies reported elevated HbA1c levels in IDA patients independent of glycemic status, potentially leading to diabetes overdiagnosis, while others found no significant association. Proposed mechanisms included altered erythrocyte turnover, structural haemoglobin modifications, and oxidative stress-induced glycation. Iron replacement therapy was shown to normalize HbA1c levels in many cases, underscoring the importance of addressing iron status in diabetic patients with concomitant anaemia. DISCUSSION: The findings highlight the need for cautious interpretation of HbA1c results in IDA patients, especially in high-risk groups like premenopausal women. Alternative glycemic markers, such as glycated albumin or fructosamine, may be valuable in such scenarios. Methodological variations in HbA1c measurement and population differences were identified as key confounding factors.
conclusionThe study underscores the intricate interplay between IDA and HbA1c, emphasizing the necessity of considering iron status in diabetes diagnosis and management. Future research should focus on standardizing assessment protocols and elucidating the molecular pathways linking iron metabolism to haemoglobin glycation. These insights are crucial for improving diagnostic accuracy and therapeutic outcomes in affected populations.
Indexed as
Identifiers
41588960What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.